Print

Clearside Biomedical Announces Plans for Clinical Testing of CLS1001 (Triamcinolone Acetonide) Suprachoroidal Injectable Suspension for the Treatment of Some Eye Diseases  
1/10/2013 9:30:39 AM

ALPHARETTA, Ga.--(BUSINESS WIRE)--Clearside Biomedical, Inc., a privately held ophthalmic company developing and commercializing targeted therapeutics for the treatment of sight threatening diseases, announced today that the standard 30-day review period by the U.S. Food and Drug Administration (FDA) relating to Clearside’s Investigational New Drug (IND) Application for CLS1001 (triamcinolone acetonide) Suprachoroidal Injectable Suspension for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids has concluded and clinical testing can proceed.
//-->